ydT cell cancer immunotherapy : evidence-based perspectives for clinical translation / Marta Barisa, editor.

Format:

Book

Contributor:

Barisa, Marta, editor.

Series:

Breaking tolerance to anti-cancer cell-mediated immunotherapy.

Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy Series

Language:

English

Subjects (All):

Cancer--Immunotherapy.

Cancer.

Physical Description:

1 online resource (0 pages)

Edition:

First edition.

Place of Publication:

London, England : Elsevier, [2025]

Summary:

γδ T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation sets out and critically discusses the current clinical and relevant preclinical γδ T cell immunotherapy landscape.In five chapters, field experts discuss the challenges facing γδ T cell oncoimmunotherapy, propose solutions, and map next steps.Particular attention.

Contents:

Intro

γδ T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation

Copyright

Cover Image Insert

Aims and scope of series ``Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy´´

About the series editor

Acknowledgments

Volume editor biography

Preface

Contents

Contributors

Chapter 1: Exploiting fundamental γδ T cell immunobiology in cancer immunotherapy

Introduction

γδ T cells: A third lineage of adaptive lymphocytes retained in vertebrates

γδ T cell subsets exhibit distinct immunobiology

Vγ9Vδ2 T cells

Non-Vγ9Vδ2 T cells

Emerging principles of human γδ T cell tissue homing

Expression of activating and inhibitory receptors

Vδ2neg T cells in the peripheral blood

A 360 review of γδ T cell effector functions

γδ T cell contributions to tumor immunosurveillance and progression: Evidence from mouse models

Emerging immunotherapeutic strategies

Expansion of Vγ9Vδ2 T cells

Expanded Vδ2neg T cells

CAR-armed γδ T cells

γδ TCR gene transfer approaches

Therapeutic antibodies and other biotherapeutics

Human γδ T cells in immunotherapy

Conclusions

References

Chapter 2: Examining γδ T cell receptor (γδ-TCR) structure and signaling in the context of&amp

s

The anatomy of a chimeric antigen receptor

TCR ectodomains and transmembrane regions

Mode of TCR/antigen engagement

TCR signaling machinery

Early TCR signal transduction and the role of co-stimulation

TCR signal propagation

The TCR-mediated immune synapse

Discussion and conclusion

Chapter 3: γδ T cell immunotherapy: Requirement for combinations?

Conflict of interest

Tumor microenvironment suppresses γδ T cells.

Metabolic-mediated suppression of γδ T cells

Hypoxia-mediated suppression of γδ T cells

Immune checkpoint-mediated suppression of γδ T cells

PD1

BTLA

TIM3

ICI therapy or chemotherapy in combination with other therapy

Conclusion

Chapter 4: Appraising γδ T cell exhaustion and differentiation in the context of synthetic engineeri

The power of T cell adoptive transfer to eradicate cancers

Engineered αβ T cells in adoptive transfer: State of the art

γδ T lymphocytes show significant functional and phenotypic differences from αβ T cells

Anticancer properties mediated by the γδ T cell receptor and options for exploitation in synthetic biology

Natural killer type receptors and innate anticancer reactivity

Co-stimulation of the γδ T cell

Professional antigen presentation by γδ T cells

Choice of differentiation state for γδ T cell adoptive transfer

Current knowledge on optimal T memory populations for adoptive transfer in the αβ T cells field

Evidence of optimal γδ T memory/stem populations for adoptive transfer

γδ T cell exhaustion

Classical αβ T checkpoint inhibitors and their effects on γδ T cells

Putative innate-specific checkpoint pathways and their inhibition

Current progress in γδ T cell engineering

Considerations of optimal CAR structure for evaluation in γδ T lymphocytes

Fine-tuning for differential antigen sensing

A platform for allogeneic cell therapy?

Concluding remarks

Acknowledgment

Chapter 5: γδ T cells for cancer immunotherapy: A 2024 comprehensive systematic review of clinical trials

Results

Broad overview

Trial location

Trial indications

Types of γδ T interventions

Solid tumor targeting

Hematological cancer targeting: Mixed results.

Allogeneic γδ T cell adoptive transfer trials

Choice of γδ T cell subset for allogeneic trials

Allogeneic trial dosing and preconditioning

Modified γδ T cell adoptive transfer trials

Overview

Modification strategies

Discussion and future perspectives

Appendix

Chapter 6: Allograft persistence: The next frontier for allogeneic γδ T cell therapy

Preconditioning

Chemotherapy

Antibody therapy

Immunosuppressants

Stealth engineering

Index.

Notes:

Includes bibliographical references and index.

Description based on publisher supplied metadata and other sources.

Description based on print version record.

ISBN:

0-443-21767-X

0-443-21766-1

OCLC:

1517397171